Thema: Patent: Treatment of cancer with 2-deoxyglucose
Patent: Treatment of cancer with 2-deoxyglucose
Benutzer81
06.01.2006 11:57:43
United States Patent 6,979,675 - Tidmarsh - December 27, 2005
Treatment of cancer with 2-deoxyglucose
Abstract
The compound 2-deoxyglucose can be used to treat cancer and to improve patient outcome when administered at a therapeutically effective dose, and, optionally, co-administered with other anti-cancer drugs, or in combination with surgical resection or radiation therapy.
-----------------------------------------------------------------------------
1. A method of treating cancer in a human cancer patient, which method comprises administering to said patient a therapeutically effective dose of 2-deoxy-D-glucose (2-DG), said therapeutically effective dose obtained by orally administering 2-DG daily to said patient in a range of about 25 mg of 2-DG per kg of patient weight to about 150 mg of 2-DG per kg of patient weight for at least five consecutive days.
2. The method of claim 1 wherein said 2-DG is administered daily for at least two weeks.
3. The method of claim 1, wherein said 2-DG is administered daily for at least one week.
4. The method of claim 1, wherein said 2-DG is administered daily for at least ten consecutive days.
5. The method of claim 1, wherein said daily dose is in the range of about 1 mg of 2-DG per kg of patient weight to about 1 g/kg.
6. The method of claim 1, wherein said daily dose is in the range of about 25 mg/kg to about 50 mg/kg.
7. A method of treating a human cancer patient, which method comprises administering to said patient a therapeutically effective dose of 2-DG in combination with another anti-cancer agent, wherein the therapeutically effective dose of 2-DG is obtained by orally administering 2-DG daily in a range of about 25 mg of 2-DG per kg of patient weight to about 150 mg of 2-DG per kg of patient weight for at least five consecutive days.
8. The method of claim 7, wherein said cancer is a multi-drug resistant cancer.
9. The method of claim 8, wherein said anti-cancer agent is an agent to which said cancer is resistant in the absence of 2-DG.
10. The method of claim 7, wherein said anti-cancer agent is administered to the mammal at a dose that is lower than the recommended effective dose for administration when not administered in combination with 2-DG.
11. The method of claim 7, wherein said cancer is a cancer selected from the group consisting of non-small-cell lung cancer, head and neck cancer, colorectal cancer, and breast cancer.
12. The method of claim 7, wherein said therapeutically effective dose of 2-DG is obtained by administering 2-DG daily for at least a week.
13. The method of claim 7, wherein said anti-cancer agent is selected from the group consisting of docetaxel, paclitaxel, cisplatin, and carboplatin.
14. A method of treating cancer in a human patient having a solid tumor, which method comprises administering to said patient a therapeutically effective dose of 2-deoxy-D-glucose (2-DG), said therapeutically effective dose obtained by orally administering 2-DG daily in a range of about 25 mg of 2-DG per kg of patient weight to about 150 mg of 2-DG per kg of patient weight for at least five consecutive days.
15. A method of treating cancer in a human cancer patient, which method comprises co-administering to said patient (i) a therapeutically effective dose of 2-deoxy-D-glucose (2-DG), said therapeutically effective dose obtained by orally administering 2-DG daily in a range of about 25 mg of 2-DG per kg of patient weight to about 150 mg of 2-DG per kg of patient weight for at least five consecutive days, and (ii) an anti-cancer agent selected from the group consisting of docetaxel, paclitaxel, cisplatin, and carboplatin.
16. The method of claim 15, wherein said patient has a solid tumor cancer.
17. The method of claim 1, wherein said patient has a solid tumor cancer.
Treatment of cancer with 2-deoxyglucose
Abstract
The compound 2-deoxyglucose can be used to treat cancer and to improve patient outcome when administered at a therapeutically effective dose, and, optionally, co-administered with other anti-cancer drugs, or in combination with surgical resection or radiation therapy.
-----------------------------------------------------------------------------
1. A method of treating cancer in a human cancer patient, which method comprises administering to said patient a therapeutically effective dose of 2-deoxy-D-glucose (2-DG), said therapeutically effective dose obtained by orally administering 2-DG daily to said patient in a range of about 25 mg of 2-DG per kg of patient weight to about 150 mg of 2-DG per kg of patient weight for at least five consecutive days.
2. The method of claim 1 wherein said 2-DG is administered daily for at least two weeks.
3. The method of claim 1, wherein said 2-DG is administered daily for at least one week.
4. The method of claim 1, wherein said 2-DG is administered daily for at least ten consecutive days.
5. The method of claim 1, wherein said daily dose is in the range of about 1 mg of 2-DG per kg of patient weight to about 1 g/kg.
6. The method of claim 1, wherein said daily dose is in the range of about 25 mg/kg to about 50 mg/kg.
7. A method of treating a human cancer patient, which method comprises administering to said patient a therapeutically effective dose of 2-DG in combination with another anti-cancer agent, wherein the therapeutically effective dose of 2-DG is obtained by orally administering 2-DG daily in a range of about 25 mg of 2-DG per kg of patient weight to about 150 mg of 2-DG per kg of patient weight for at least five consecutive days.
8. The method of claim 7, wherein said cancer is a multi-drug resistant cancer.
9. The method of claim 8, wherein said anti-cancer agent is an agent to which said cancer is resistant in the absence of 2-DG.
10. The method of claim 7, wherein said anti-cancer agent is administered to the mammal at a dose that is lower than the recommended effective dose for administration when not administered in combination with 2-DG.
11. The method of claim 7, wherein said cancer is a cancer selected from the group consisting of non-small-cell lung cancer, head and neck cancer, colorectal cancer, and breast cancer.
12. The method of claim 7, wherein said therapeutically effective dose of 2-DG is obtained by administering 2-DG daily for at least a week.
13. The method of claim 7, wherein said anti-cancer agent is selected from the group consisting of docetaxel, paclitaxel, cisplatin, and carboplatin.
14. A method of treating cancer in a human patient having a solid tumor, which method comprises administering to said patient a therapeutically effective dose of 2-deoxy-D-glucose (2-DG), said therapeutically effective dose obtained by orally administering 2-DG daily in a range of about 25 mg of 2-DG per kg of patient weight to about 150 mg of 2-DG per kg of patient weight for at least five consecutive days.
15. A method of treating cancer in a human cancer patient, which method comprises co-administering to said patient (i) a therapeutically effective dose of 2-deoxy-D-glucose (2-DG), said therapeutically effective dose obtained by orally administering 2-DG daily in a range of about 25 mg of 2-DG per kg of patient weight to about 150 mg of 2-DG per kg of patient weight for at least five consecutive days, and (ii) an anti-cancer agent selected from the group consisting of docetaxel, paclitaxel, cisplatin, and carboplatin.
16. The method of claim 15, wherein said patient has a solid tumor cancer.
17. The method of claim 1, wherein said patient has a solid tumor cancer.
Benutzer81
